Dr. Sasine on New Developments With CAR T-Cell Therapy

Video

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

Follow-up data from the initial trials of CAR T-cell therapy continue to show benefit with this approach. Moreover, providers have become more accustomed to how to use these therapies. In doing so, they have learned how to make these products safer and predict which patients are most likely to benefit from them. Such strategies include inhibiting cytokines that have a direct implication on the neurotoxicity of the CAR T cells, says Sasine. Another approach is bispecific CAR T cells, which are designed to eradicate one of the escape mechanisms that cancer cells have to avoid CAR T cell recognition.

It’s difficult to predict the likelihood of response to CAR T-cell therapy on an individualized level. However, the field is beginning to understand that there are certain cytokine profiles both before and after CAR T cells are administered that are associated with durable remissions. Moreover, there are certain pre-therapeutic indicators of response, including the depth of conditioning for CAR T cells. Notably, the depth of lymphodepletion can be modified, whereas other factors are merely predictive, concludes Sasine.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.